DALPL: Building India’s next-gen of specialised testing capabilities 

From a food and agricultural testing laboratory to a specialised pharma testing facility, the company’s journey reflects the evolution of India’s analytical testing industry. In this conversation, Ashay Mehta, Founder & Managing Director of Doctors’ Analytical Laboratories Pvt Ltd (DALPL) discusses regulatory compliance, data integrity, emerging testing requirements, talent challenges and plans to expand into peptides, topical products and medical device testing with Swati Rana 

DALPL was established in 2006 with a food and agricultural testing laboratory and has since expanded into pharmaceutical testing and other verticals. How has the journey been, and what have been the key milestones?

We started in 2006 in Pune as a food and general testing laboratory, when food regulations in India were still developing. At the time, regulatory requirements were largely linked to exports of certain commodities to Europe. I joined the business in 2008. It was a family investment that we subsequently spearheaded and developed into what it is today.

In 2011–12, we decided to move the facility from Pune to Mumbai. Since we were based in Mumbai, the move offered better operational control and opportunities for expansion. Mumbai also provided a strategic advantage because of its connectivity to ports and its accessibility to customers and sample sources across Gujarat, Goa and other regions. We re-established our operations in Mumbai in 2012.

Although India’s food safety law had been enacted earlier and came into effect in 2011, awareness remained limited. The Maggi controversy in 2015 brought food safety and testing into sharper public focus, and the industry has continued to develop since then, although growth has been uneven.

Around 2012–13, we also began exploring pharmaceutical testing. We entered the segment gradually, starting with one area where regulatory requirements were still evolving.

In 2016, we underwent our first US FDA inspection at a facility where we were conducting both food and pharmaceutical testing. The experience made us realise that if we wanted to pursue pharmaceutical testing seriously, we needed a dedicated facility, team, standard operating procedures (SOPs) and quality management systems (QMS). Food and pharmaceutical testing require different operating environments and approaches, and we felt that both could not be managed effectively within the same facility.

We therefore took the decision to shut down our pharmaceutical testing operations temporarily and invest in a dedicated facility, even though it meant losing the business we had built in that segment. We developed the new facility and opened it in September 2017.

In May 2018, we received our first US FDA Establishment Inspection Report (EIR), following an inspection conducted shortly after we moved to the new premises. We were inspected again in 2022. During the COVID-19 period, one of our clients was facing delays in securing approvals because our facility had not been reinspected. We approached the FDA, explained the situation and requested an inspection on our client’s behalf. The agency conducted the inspection, and we received a Form 483 with observations.

We have since continued to strengthen our compliance capabilities. Our facility has undergone audits supporting work for clients in Canada and Europe, including an audit by a Qualified Person (QP) representing a client. Our regulatory experience spans the US, European and Canadian markets, as well as Australia.

How has India’s analytical testing ecosystem evolved over the past two decades?

When we entered the market, there were very few laboratories serving the highly regulated pharmaceutical testing segment. In 2017, there were only around six or seven laboratories in India with US FDA approval, based on our understanding at the time.

Today, the landscape has changed considerably. There has been a substantial increase in the number of testing laboratories, particularly in pharmaceutical hubs such as Hyderabad. Food testing has also expanded rapidly, with new laboratories entering the market regularly.

However, the growth of laboratory infrastructure has not always been matched by the development of specialised talent. The industry needs experienced professionals who understand complex analytical techniques, regulatory expectations, quality systems and the demands of international inspections.

Regulatory compliance is another important consideration. Establishing a laboratory is one thing; sustaining compliance through inspections and consistently meeting regulatory expectations is another. Laboratories must invest continuously in people, systems, equipment and processes.

The ecosystem is developing rapidly, and I believe the availability of specialised talent and expertise will improve over time. For now, however, workforce development remains an important area of focus.

What are the biggest challenges pharmaceutical companies face when it comes to analytical testing in India?

The encouraging development is that Indian laboratories can now provide a wide range of specialised testing services that companies previously had to seek from laboratories in Europe or the US. These include in vitro release testing (IVRT), in vitro permeation testing (IVPT), nitrosamine analysis, extractables and leachables studies, and peptide-related testing.

Companies no longer need to depend as heavily on overseas laboratories or face the same waiting periods for many of these services. The domestic ecosystem has developed the infrastructure and expertise needed to support increasingly complex testing requirements.

The industry is also seeing greater government participation in laboratory development. Support schemes and subsidies for setting up testing infrastructure can help expand capacity in areas where specialised facilities are required.

The opportunity now is to ensure that this infrastructure continues to evolve alongside regulatory requirements, emerging technologies and the growing complexity of pharmaceutical products.

With increasing regulatory scrutiny, what changes are you seeing in documentation and quality systems across pharmaceutical testing laboratories?

We began seeing a significant shift in 2016–17, which was one of the reasons we decided to establish a dedicated pharmaceutical testing facility.

Regulatory testing requires extensive documentation, whether in food or pharmaceuticals. In pharmaceutical testing, traceability must be maintained throughout the process, from sample receipt and registration to testing, reporting and eventual sample disposal.

Our systems are designed to maintain complete traceability. The analytical instruments and associated systems are configured with appropriate user access controls and privileges. These controls help prevent unauthorised deletion or manipulation of records and chromatographic data.

Regulatory expectations have become increasingly stringent, but customer expectations have evolved as well. A decade ago, laboratories could encounter resistance when they explained that a particular request could not be accommodated because of regulatory requirements. Customers might point to another laboratory that was willing to do it differently.

Today, customers increasingly recognise the importance of compliance, data integrity and reliable testing, particularly given the investment involved in pharmaceutical development and regulatory approvals. Responsible customers understand that compromising testing integrity can create significant risks for their products and businesses.

Overall, regulatory expectations and customer awareness are moving in the same direction, encouraging better practices across the ecosystem.

Are Indian testing laboratories keeping pace with global regulatory standards?

Yes, India is keeping pace with global regulatory standards, and the development of the domestic testing ecosystem reflects that progress.

Regulatory requirements should not be viewed simply as a burden on the industry. They ultimately help ensure product quality and patient safety. The challenge is to develop the capabilities, infrastructure and expertise needed to meet those requirements consistently.

India continues to face competitive pressures, including from China, which has significant manufacturing scale and an established industrial ecosystem. However, Indian laboratories are strengthening their capabilities and working to meet international expectations.

Continued investment in infrastructure, technology and skilled professionals will be essential to sustaining this progress.

Pharmaceutical companies often have their own analytical testing laboratories. What role do independent testing laboratories play?

Pharmaceutical companies generally use their in-house laboratories for routine quality control testing. Independent laboratories complement these capabilities by providing specialised services, particularly method development and method validation.

Developing and validating an analytical method can be time-consuming and requires specialised expertise and equipment. Once the method has been developed and validated, companies may send their samples to an independent laboratory for testing, allowing them to focus their internal resources on other activities.

Some analytical instruments are also extremely expensive, and it may not be practical for every pharmaceutical company to invest in multiple systems for specialised testing. As commercial laboratories, we can make these investments across a broader client base.

Our work is not limited to Indian companies. We serve international customers from markets including Turkey, Bangladesh, Saudi Arabia and Canada.

Customer audits are another important part of the relationship. In addition to regulatory inspections, customers typically audit our facility before starting work with us and may conduct periodic audits thereafter. This provides an additional layer of oversight and helps maintain confidence in the laboratory’s systems and capabilities.

Data integrity is a major regulatory concern. What does maintaining data integrity mean in practical terms for a testing laboratory?

Data integrity can be compromised in different circumstances. Sometimes, an employee makes an honest mistake and attempts to conceal it out of fear of reprimand. In other cases, data may be deliberately manipulated.

We address the first situation by creating an environment in which employees are encouraged to report mistakes immediately. We tell our teams that making a mistake is not necessarily the biggest problem; concealing it can create a much greater risk.

If an employee reports an error, we can investigate it, assess its impact, implement corrective measures and prevent it from recurring. If people feel pressured to hide mistakes, neither the individual nor the organisation can learn from the incident or mitigate the risk effectively.

Our approach is to encourage transparency and make employees understand that reporting an error is the right thing to do. We take responsibility for investigating the issue and determining the appropriate corrective action.

At the same time, deliberate manipulation must be prevented through robust quality systems, appropriate access controls, traceable records and a culture of accountability. Technology and procedures are important, but the right organisational culture is equally essential to maintaining data integrity.

What will pharmaceutical companies expect from analytical testing laboratories over the next five years?

Customers will increasingly expect laboratories to provide a broader range of services under one roof, along with stronger regulatory credentials and expertise across different markets.

As pharmaceutical companies expand internationally, they must comply with the requirements of individual countries and regulatory authorities. These requirements may differ, and companies need laboratory partners that understand the relevant standards and can support their testing needs.

Consequently, laboratories will need to expand their service portfolios, invest in specialised equipment, strengthen their regulatory capabilities and provide more comprehensive technical support.

The ability to respond to evolving requirements quickly and consistently will become an important differentiator.

Which areas should India’s pharmaceutical testing ecosystem prioritise over the next five to ten years?

Medical devices, peptides and topical products are three important areas.

Medical device manufacturing is receiving greater attention in India, but there is a need for more specialised testing infrastructure. Many existing laboratories offer routine testing services, while advanced and specialised requirements will call for dedicated capabilities.

Peptides also have significant potential because of their applications across pharmaceuticals and nutraceuticals. As the market develops, laboratories will need to strengthen their expertise and infrastructure to support the associated analytical and regulatory requirements.

Topical products represent another important growth area. Specialised studies, including IVRT and IVPT, help assess drug release from formulations and the permeation of active ingredients through the skin. These capabilities are important for the development and evaluation of topical pharmaceutical products.

Building specialised services around these three areas will be important to meeting future industry demand.

What are your company’s expansion plans for the coming years? How do you see the company’s growth trajectory over the next five years?

We are planning to expand both our food and pharmaceutical testing capabilities.

In 2027, we intend to move our food testing division into a larger facility next door. The additional space will allow us to introduce RT-PCR testing for genetically modified organisms (GMOs) and animal species identification.

In pharmaceutical testing, we plan to expand our work in peptides. We have already established facilities for specialised in vitro testing of topical products, including IVRT and IVPT.

We are also keen to establish a dedicated medical device testing division. However, that investment is likely to form part of a longer-term plan, potentially in the third or fourth year of our expansion programme.

Our focus remains on the life sciences, food testing and pharmaceutical testing sectors, with medical devices representing a potential future area of diversification.

We have been growing at approximately 25–30% year on year. For the 2026–27 financial year, we are targeting growth of at least 50–60%.

Given the changes taking place in food safety requirements and pharmaceutical testing, we see opportunities to expand our business. Our planned investments in additional infrastructure and specialised services are intended to support this growth.

The objective is to build on our existing capabilities while entering areas where we can offer specialised expertise and differentiated services.

Could you elaborate on the specialised pharmaceutical testing services you currently offer?

Our pharmaceutical testing portfolio covers active pharmaceutical ingredients (APIs), intermediates, finished formulations and packaging materials.

One important area is the development and validation of analytical methods for nitrosamines and nitrosamine drug substance-related impurities (NDSRIs), which are potential carcinogenic impurities that require careful assessment. We also undertake elemental impurity testing and extractables and leachables studies, which evaluate substances that may migrate from packaging materials into pharmaceutical products.

For topical products, we conduct IVRT and IVPT studies to assess drug release from formulations and the permeation of active ingredients through the skin.

We also undertake gastric and feeding-tube studies for medicines administered through feeding tubes, which may be used by post-operative patients and others who cannot take medication orally in the usual manner. These studies help evaluate drug recovery and the amount of medicine delivered through the tube. Our work can include particle-size evaluation and high-performance liquid chromatography (HPLC) assays.

Another area involves in vitro binding studies for certain gastrointestinal medicines, including products such as sucralfate and phosphate binders. These studies help assess interactions between medicines under specified conditions.

We also conduct particle-size evaluations and other specialised analytical assessments. Several of these services support product development and bioequivalence-related investigations where appropriate in vitro methods can provide useful evidence without requiring a clinical study for that particular assessment.

Our approach is not to compete purely on the number of instruments we operate. We invest in the equipment, expertise and infrastructure needed to deliver specialised projects that meet our technical and commercial requirements. We focus on areas where we can provide meaningful value rather than attempting to handle every project regardless of its complexity or commercial viability.

 

swati.rana@expressindia.com
Swatirana.express@gmail.com 

 

Ashay MehtaDALPLdata integritymedical device testingpeptidesRegulatorytalent challengestopical products
Comments (0)
Add Comment